Biomarkers for cognitive dysfunction diseases and method for detecting cognitive dysfunction disease using biomarkers

Abstract

Biomarkers for detecting cognitive dysfunction diseases and methods for detecting cognitive dysfunction diseases using the biomarkers are provided. A method for detecting cognitive dysfunction diseases comprising measuring one or more biomarkers for detecting cognitive dysfunction diseases selected from the following (a), (b), and (c) in a biological sample simultaneously or separately: (a) a biomarker for detecting cognitive dysfunction diseases consisting of an intact protein of apolipoprotein A1 comprising the amino acid sequence represented by SEQ ID NO:1 or a partial peptide thereof; (b) a biomarker for detecting cognitive dysfunction diseases consisting of an intact protein of transthyretin comprising the amino acid sequence represented by SEQ ID NO:2 or a partial peptide thereof; and (c) a biomarker for detecting cognitive dysfunction diseases consisting of an intact protein of complement C3 comprising the amino acid sequence represented by SEQ ID NO:3 or a partial peptide thereof.

1 - 7 . (canceled) 
     
     
         8 . One or more biomarkers for detecting cognitive dysfunction diseases selected from the following (a), (b), and (c):
 (a) a biomarker for detecting cognitive dysfunction diseases consisting of an intact protein of apolipoprotein A1 comprising the amino acid sequence represented by SEQ ID NO:1 or a partial peptide thereof;   (b) a biomarker for detecting cognitive dysfunction diseases consisting of an intact protein of transthyretin comprising the amino acid sequence represented by SEQ ID NO:2 or a partial peptide thereof; and   (c) a biomarker for detecting cognitive dysfunction diseases consisting of an intact protein of complement C3 comprising the amino acid sequence represented by SEQ ID NO:3 or a partial peptide thereof.   
     
     
         9 . A method for detecting cognitive dysfunction diseases comprising measuring one or more biomarkers for detecting cognitive dysfunction diseases selected from the following (a), (b), and (c) in a biological sample simultaneously or separately:
 (a) a biomarker for detecting cognitive dysfunction diseases consisting of an intact protein of apolipoprotein A1 comprising the amino acid sequence represented by SEQ ID NO:1 or a partial peptide thereof;   (b) a biomarker for detecting cognitive dysfunction diseases consisting of an intact protein of transthyretin comprising the amino acid sequence represented by SEQ ID NO:2 or a partial peptide thereof; and   (c) a biomarker for detecting cognitive dysfunction diseases consisting of an intact protein of complement C3 comprising the amino acid sequence represented by SEQ ID NO:3 or a partial peptide thereof.   
     
     
         10 . The method for detecting cognitive dysfunction diseases according to  claim 9  comprising measuring two biomarkers, namely, the (c) biomarker and the (a) biomarker or the (b) biomarker. 
     
     
         11 . The method for detecting cognitive dysfunction diseases according to  claim 9  comprising measuring two biomarkers, namely, the (c) biomarker and the (a) biomarker when the detection of the cognitive dysfunction diseases is the detection of mild cognitive impairment or measuring two biomarkers, namely, the (c) biomarker and the (b) biomarker when the detection of the cognitive dysfunction diseases is Alzheimer's disease. 
     
     
         12 . A cognitive dysfunction disease detection kit for measuring one or more biomarkers for detecting cognitive dysfunction diseases selected from the following (a), (b), and (c):
 (a) a biomarker for detecting cognitive dysfunction diseases consisting of an intact protein of apolipoprotein A1 comprising the amino acid sequence represented by SEQ ID NO:1 or a partial peptide thereof;   (b) a biomarker for detecting cognitive dysfunction diseases consisting of an intact protein of transthyretin comprising the amino acid sequence represented by SEQ ID NO:2 or a partial peptide thereof; and   (c) a biomarker for detecting cognitive dysfunction diseases consisting of an intact protein of complement C3 comprising the amino acid sequence represented by SEQ ID NO:3 or a partial peptide thereof.   
     
     
         13 . The cognitive dysfunction disease detection kit according to  claim 12  comprising an antibody against the biomarker or aptamer. 
     
     
         14 . A method for selecting a combination of multiple biomarkers for detecting cognitive dysfunction diseases which gives a high percentage of correct answers comprising:
 measuring two or more biomarkers for cognitive dysfunction diseases in a biological sample from a subject;   conducting an analysis of the measurement results of each of the two or more biomarkers by a logistic regression analysis; and   selecting a combination of the biomarkers for detecting cognitive dysfunction diseases which gives a high percentage of correct answers based on the results of the analysis.